JP2009507829A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009507829A5 JP2009507829A5 JP2008529964A JP2008529964A JP2009507829A5 JP 2009507829 A5 JP2009507829 A5 JP 2009507829A5 JP 2008529964 A JP2008529964 A JP 2008529964A JP 2008529964 A JP2008529964 A JP 2008529964A JP 2009507829 A5 JP2009507829 A5 JP 2009507829A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- formula
- cancer
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 61
- -1 alkoxyheteroaryl Chemical group 0.000 claims 14
- 125000003342 alkenyl group Chemical group 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000000304 alkynyl group Chemical group 0.000 claims 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 125000002252 acyl group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 125000004404 heteroalkyl group Chemical group 0.000 claims 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 8
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 125000006239 protecting group Chemical group 0.000 claims 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 6
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- 102000003964 Histone deacetylase Human genes 0.000 claims 4
- 108090000353 Histone deacetylase Proteins 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 125000001769 aryl amino group Chemical group 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 125000004442 acylamino group Chemical group 0.000 claims 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims 3
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000005133 alkynyloxy group Chemical group 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 125000000524 functional group Chemical group 0.000 claims 3
- 125000000262 haloalkenyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 3
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000007737 Retinal degeneration Diseases 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000232 haloalkynyl group Chemical group 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 230000004258 retinal degeneration Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000001847 2-phenylcyclopropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 claims 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 229920000298 Cellophane Polymers 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000003495 Coccidiosis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 claims 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065630 Iris neovascularisation Diseases 0.000 claims 1
- 206010023076 Isosporiasis Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010023335 Keratitis interstitial Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010057168 Leishmania infections Diseases 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000002367 Retinal Perforations Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 206010044074 Torticollis Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 201000005485 Toxoplasmosis Diseases 0.000 claims 1
- 241000223104 Trypanosoma Species 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 229940095731 candida albicans Drugs 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 210000000795 conjunctiva Anatomy 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 125000004465 cycloalkenyloxy group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000004340 degenerative myopia Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000018197 inherited torticollis Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000006904 interstitial keratitis Diseases 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000029233 macular holes Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004379 myopia Effects 0.000 claims 1
- 208000001491 myopia Diseases 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 108010040003 polyglutamine Proteins 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 230000001148 spastic effect Effects 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000018724 torsion dystonia Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71482705P | 2005-09-08 | 2005-09-08 | |
| US60/714,827 | 2005-09-08 | ||
| US78381906P | 2006-03-21 | 2006-03-21 | |
| US60/783,819 | 2006-03-21 | ||
| PCT/SG2006/000217 WO2007030080A1 (en) | 2005-09-08 | 2006-08-01 | Heterocyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009507829A JP2009507829A (ja) | 2009-02-26 |
| JP2009507829A5 true JP2009507829A5 (enExample) | 2009-09-10 |
| JP5207064B2 JP5207064B2 (ja) | 2013-06-12 |
Family
ID=37836122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008529964A Expired - Fee Related JP5207064B2 (ja) | 2005-09-08 | 2006-08-01 | 複素環化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8143282B2 (enExample) |
| EP (1) | EP1937650B1 (enExample) |
| JP (1) | JP5207064B2 (enExample) |
| KR (1) | KR101346823B1 (enExample) |
| AR (1) | AR055364A1 (enExample) |
| AT (1) | ATE512953T1 (enExample) |
| BR (1) | BRPI0615690B8 (enExample) |
| CY (1) | CY1111789T1 (enExample) |
| DK (1) | DK1937650T3 (enExample) |
| MY (1) | MY144970A (enExample) |
| NZ (1) | NZ594108A (enExample) |
| PL (1) | PL1937650T3 (enExample) |
| PT (1) | PT1937650E (enExample) |
| TW (1) | TWI393708B (enExample) |
| WO (1) | WO2007030080A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7781595B2 (en) | 2003-09-22 | 2010-08-24 | S*Bio Pte Ltd. | Benzimidazole derivatives: preparation and pharmaceutical applications |
| DE102007037579B4 (de) | 2007-08-09 | 2012-05-16 | Emc Microcollections Gmbh | Neue Benzimidazol-2-yl-alkylamine und ihre Anwendung als mikrobizide Wirkstoffe |
| WO2009084544A1 (ja) * | 2007-12-27 | 2009-07-09 | Idemitsu Kosan Co., Ltd. | 含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子 |
| US20110212943A1 (en) * | 2008-10-15 | 2011-09-01 | Orchid Research Laboratories Limited | Novel bridged cyclic compounds as histone deacetylase inhibitors |
| KR101168801B1 (ko) * | 2009-03-27 | 2012-07-25 | 주식회사종근당 | 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물 |
| US20110245154A1 (en) * | 2010-03-11 | 2011-10-06 | Hemaquest Pharmaceuticals, Inc. | Methods and Compositions for Treating Viral or Virally-Induced Conditions |
| PT2624696T (pt) | 2010-10-06 | 2017-03-21 | Glaxosmithkline Llc | Derivados de benzimidazole como inibidores da cinase pi3 |
| CA2866333C (en) * | 2011-03-09 | 2020-12-29 | Cereno Scientific Ab | Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors |
| WO2012127466A1 (en) * | 2011-03-24 | 2012-09-27 | Bar Ilan University | 5-aminolevulinic acid derivatives, methods for their preparation and uses thereof |
| US20150258068A1 (en) * | 2012-10-30 | 2015-09-17 | Mei Pharma, Inc. | Combination therapies |
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| US10723705B2 (en) | 2015-08-14 | 2020-07-28 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| CN114209667A (zh) | 2016-04-08 | 2022-03-22 | 赛伦诺科技有限公司 | 包含丙戊酸的延迟释放药物制剂和其用途 |
| AR108257A1 (es) | 2016-05-02 | 2018-08-01 | Mei Pharma Inc | Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas |
| EP3728205A1 (en) | 2017-12-19 | 2020-10-28 | Assia Chemical Industries Ltd | Crystalline polymorphs of pracinostat and pracinostat salts |
| KR102106032B1 (ko) * | 2018-08-24 | 2020-04-29 | 인제대학교산학협력단 | 프라시노스타트를 포함하는 다발성 경화증 치료용 약학 조성물 |
| KR102162744B1 (ko) * | 2018-09-18 | 2020-10-07 | 인제대학교산학협력단 | 프라시노스타트를 포함하는 염증성 장질환 치료용 약학 조성물 |
| CN110950848B (zh) * | 2018-09-27 | 2024-03-26 | 徐诺药业 | 新型氨基吡唑类衍生物的合成与应用 |
| SG11202113215UA (en) | 2019-05-31 | 2021-12-30 | Viracta Subsidiary Inc | Methods of treating virally associated cancers with histone deacetylase inhibitors |
| WO2021217180A1 (en) * | 2020-04-22 | 2021-10-28 | Johnson Matthey Public Limited Company | Novel forms of pracinostat dihydrochloride |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1608628A2 (en) * | 2003-03-17 | 2005-12-28 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| AR043850A1 (es) * | 2003-04-17 | 2005-08-17 | Bayer Pharmaceuticals Corp | Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos |
| US7781595B2 (en) * | 2003-09-22 | 2010-08-24 | S*Bio Pte Ltd. | Benzimidazole derivatives: preparation and pharmaceutical applications |
| WO2005066151A2 (en) * | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
-
2006
- 2006-08-01 NZ NZ594108A patent/NZ594108A/xx not_active IP Right Cessation
- 2006-08-01 KR KR1020087007856A patent/KR101346823B1/ko not_active Expired - Fee Related
- 2006-08-01 BR BRPI0615690A patent/BRPI0615690B8/pt not_active IP Right Cessation
- 2006-08-01 WO PCT/SG2006/000217 patent/WO2007030080A1/en not_active Ceased
- 2006-08-01 EP EP06769700A patent/EP1937650B1/en not_active Not-in-force
- 2006-08-01 US US12/065,989 patent/US8143282B2/en not_active Expired - Fee Related
- 2006-08-01 AT AT06769700T patent/ATE512953T1/de active
- 2006-08-01 MY MYPI20063724A patent/MY144970A/en unknown
- 2006-08-01 DK DK06769700.3T patent/DK1937650T3/da active
- 2006-08-01 JP JP2008529964A patent/JP5207064B2/ja not_active Expired - Fee Related
- 2006-08-01 TW TW095128137A patent/TWI393708B/zh not_active IP Right Cessation
- 2006-08-01 PT PT06769700T patent/PT1937650E/pt unknown
- 2006-08-01 PL PL06769700T patent/PL1937650T3/pl unknown
- 2006-08-01 AR ARP060103353A patent/AR055364A1/es not_active Application Discontinuation
-
2011
- 2011-08-30 CY CY20111100829T patent/CY1111789T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009507829A5 (enExample) | ||
| JP2008533198A5 (enExample) | ||
| JP2010522184A5 (enExample) | ||
| NL1031976C2 (nl) | N-(pyridine-2-yl)sulfonamidederivativen. | |
| CA2457444A1 (en) | 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity | |
| JP2019518766A5 (enExample) | ||
| JP2011517443A5 (enExample) | ||
| US12454516B2 (en) | Nitric oxide releasing prodrugs of MDA and MDMA | |
| JP2011515483A5 (enExample) | ||
| JP2006513268A5 (ja) | アンタゴニスト活性を有するベンゾアゾリルピペラジン誘導体 | |
| JP2012515724A5 (enExample) | ||
| JP2010524896A5 (enExample) | ||
| JP2008508247A5 (enExample) | ||
| JP2014524476A5 (enExample) | ||
| JP2012523418A5 (enExample) | ||
| US20240400511A1 (en) | Dimethyltryptamine analogues as nitric oxide delivery drugs | |
| JP2008542365A5 (enExample) | ||
| JP2008508251A5 (enExample) | ||
| JP2008508248A5 (enExample) | ||
| CA2465877C (fr) | Utilisation de derives de 2-amino-4-pyridylmethyl-thiazoline comme inhibiteurs de non-synthase inductible | |
| EP1446402A1 (fr) | Derives de 2-amino-4-heteroarylethyl thiazoline et leur utilisation comme inhibiteurs de no-synthase inductible | |
| DE60113689T2 (de) | 2-aminothiazolinderivate und ihre verwendung als no-synthase inhibitoren | |
| JP2008508250A5 (enExample) | ||
| JP2001525321A (ja) | アミノベンゾチアゾール誘導体 | |
| US12459956B2 (en) | Heterobicyclic carboxamides and uses thereof |